BNC-210

Sale of Bionomics’ French Subsidiaries to Domain Therapeutics

Retrieved on: 
수요일, 12월 11, 2019
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Cell signaling, Nicotinic antagonists, Anxiolytics, BNC-210, Dipeptides, Ion channels, Nicotinic acetylcholine receptor, Receptor

The sale price of 1,810,028.97 is the amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates and this debt will be assumed by Domain upon acquisition of the Companies.

Key Points: 
  • The sale price of 1,810,028.97 is the amount of intercompany debt owed by Bionomics to the subsidiaries for the scientific research conducted by them on Bionomics drug candidates and this debt will be assumed by Domain upon acquisition of the Companies.
  • We are pleased with the outcome of the sale of our French subsidiaries which is part of our ongoing cost reduction process, consolidation of our operations in Adelaide and focus on the clinical development of BNC210 for post-traumatic stress disorder, said Dr. Errol De Souza, Executive Chairman of Bionomics.
  • The offer from Domain is subject to satisfaction of a number of conditions precedent, including entering into definitive contractual documentation satisfactory to both parties and regulatory approval.
  • Bionomics lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (7) nicotinic acetylcholine receptor.

Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD

Retrieved on: 
월요일, 11월 4, 2019
FDA, Mental health, Health, Pharmaceutical, Clinical trials, Articles, Health, Nicotinic antagonists, Psychiatry, Food and Drug Administration, Fast track, RTT, BNC-210, Posttraumatic stress disorder

FDAs decision to grant Fast Track designation is an important recognition of the high unmet medical need in PTSD and potential benefits of BNC210 with a novel mechanism of action in the treatment of this disorder, said Dr. Errol De Souza, Executive Chairman of Bionomics.

Key Points: 
  • FDAs decision to grant Fast Track designation is an important recognition of the high unmet medical need in PTSD and potential benefits of BNC210 with a novel mechanism of action in the treatment of this disorder, said Dr. Errol De Souza, Executive Chairman of Bionomics.
  • We look forward to taking advantage of the Fast Track designation and working closely with FDA in the design and initiation of the next Phase 2b study in PTSD patients.
  • Fast Track designation is a FDA program intended to facilitate and expedite development and review of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition.
  • Bionomics lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (7) nicotinic acetylcholine receptor.